Chinese oncology company Genetron Health reported on Thursday the receipt of approval from China's National Medical Products Administration for the launch of GENETRON S5 for clinical use.
GENETRON S5 can be used in early screening, diagnosis, treatment guidance and continuous monitoring with assays for gliomas, lung cancer, urothelial cancer, breast cancer and thyroid cancer.
A semiconductor-based next generation sequencing (NGS) system, GENETRON S5 detects changes in pH value in nucleotides. It does not require fluorescence or camera scanning, resulting in faster, simpler and more cost-effective tests with a smaller sample size, the company said.
According to Genetron Health, GENETRON S5 leverages high speed semiconductor sequencing technology to produce high-quality sequencing data, enabling laboratory technicians to go from DNA library to data in as little as 24 hours. This is based on its patented One-Step Seq Method, which facilitates the preparation of high-quality libraries in less than two hours from as little as 10ng input samples.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886